Johnson & Johnson may be taking a back seat in the hepatitis C market, but it is looking more competitive in the HIV/AIDS sector, where just-released top-line 48-week efficacy and safety data from the Phase III EMERALD study show a lack of virologic rebound and similar virologic suppression and safety associated with the company’s darunavir-based once-daily single-tablet regimen to with multi-pill therapies being taken by control patients.
In announcing the results, J&J's Janssen Pharmaceutica NV and AIDS researchers highlighted the likely better adherence of patients to...
Welcome to Scrip
Create an account to read this article
Already a subscriber?